Epitel Lands $26M Series B for Remote EEG Expansion

Epitel, a developer of AI-driven wireless brain health tech, has closed a $26 million Series B financing co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors.

The Salt Lake City, Utah-based company said the funding will power continued market expansion of its REMI remote EEG monitoring system. It aims to allow extended duration wireless EEG monitoring integrated with AI-driven event detection, improving access to neurological care.

Epitel is initially targeting seizure detection and diagnosis, an area where limited EEG access and the short duration of traditional 72-hour monitoring can delay diagnosis for months.

The wearable REMI Remote EEG monitoring system enables weeks-long at-home brain monitoring, while REMI Vigilenz AI flags potential seizures to streamline review of extended EEG recordings. The platform is cleared for neurological monitoring in patients as young as one year old, with AI-assisted event detection available for ages six and older.

The Series B capital will specifically fund commercial infrastructure expansion, provider adoption, and ambulatory market access growth, Epitel said.

Comments from Epitel, clinicians, and Catalyst Health

Steve Pacelli, president and CEO of Epitel: “Millions of Americans with suspected seizures still face significant barriers to diagnosis because access to EEG remains limited, particularly outside major medical centers. We built the REMI System to help close that gap by bringing longer-term neurological monitoring closer to patients and helping clinicians efficiently review the data needed to make a diagnosis. Closing this Series B round represents a pivotal milestone for our team. With these resources, we are aggressively building out our commercial footprint by expanding our dedicated field team to get REMI into the hands of those who will most benefit from it.”

Dr. Daniel Friedman, MD, professor and director, Division of Epilepsy, NYU Langone Health: “Seizures are unpredictable, and many patients are often unaware of them. Established EEG tools for objectively assessing seizure burden have been limited by monitoring duration, as in ambulatory EEG, or by cost and an unnatural setting, as in inpatient video EEG monitoring. REMI provides a new solution for diagnosis and disease tracking on clinically relevant timescales of days to weeks, in a patient-friendly, convenient way.”

Joshua Phillips, founder and managing partner, Catalyst Health Ventures: “The ambulatory EEG market has needed this kind of disruption for decades, and Epitel has built the right solution at the right moment. This round gives the team the runway to move fast and meet the demand that’s already there. The technology is groundbreaking, but what really positions Epitel to transform brain health monitoring care is their clarity of purpose.”